High-dose rate brachytherapy as monotherapy in prostate cancer: A systematic review of its safety and efficacy

• Published in: Actas urológicas españolas (English ed.) Vol. 41; no. 2; pp. 71 - 81
• Main Authors: Sánchez-Gómez, L.M, Polo-deSantos, M, Rodríguez-Melcón, J.I, Angulo, J.C, Luengo-Matos, S
• Format: Journal Article
• Language: English
• Published: Elsevier España 01-03-2017
• Subjects: Braquiterapia de alta tasa de dosis; Cáncer de próstata; High-dose rate brachytherapy; Prostate cancer; Radiation therapy; Radioterapia; Revisión sistemática; Systematic review; Urology; Cáncer de próstata; High-dose rate brachytherapy; Systematic review; Radiation therapy; Revisión sistemática; Braquiterapia de alta tasa de dosis; Prostate cancer; Radioterapia
• ISSN: 2173-5786; 2173-5786
• DOI: 10.1016/j.acuroe.2016.12.001

Abstract Context High-dose rate brachytherapy (HDR-BT) is an increasingly popular treatment for patients with localized prostate cancer (PC). Objective To assess the safety and efficacy of HDR-BT as monotherapy in PC. Acquisition of evidence A systematic literature review was conducted through searches on MEDLINE (PubMed), Cochrane Library, CDR, ClinicalTrials and EuroScan. We assessed safety and efficacy indicators. Summary of the evidence We selected 2 reviews and 12 uncontrolled studies, included in these 2 reviews. In terms of efficacy, local control in 6 studies was 97–100%. The biochemical progression-free survival varied as follows: 85–100% for low risk and 79–92% for high risk. Survival free of metastases was >95% at 8 years, except in one study where the survival rate was 87% at 5 years. The overall survival was ≥95% in 8 studies. In terms of safety, most of the studies recorded acute and long-term genitourinary and gastrointestinal complications, especially grade ≥2. Only 3 studies found grade 4 complications. All studies, except for one without complications, observed genitourinary complications that were more frequent and severe than the gastrointestinal complications. Two studies assessed the quality of life and showed an initial reduction in various domains and subsequent partial or total recovery, except in the sexual domain. Conclusions HDR-BT is effective as monotherapy, especially in cases of low to intermediate risk. There is insufficient information on high-risk patients. The short to medium-term toxicity was acceptable. Further research needs to be funded to provide more information on the long-term safety and efficacy of this treatment.